Skip to main content
PneumoniaLungs and breathingDrugPhase 2

What this study is

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

What's being tested

  • agenT-797

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

  • Standard of Care (SOC)

    Intervention · DRUG

    Antimicrobial therapy and corticosteroids per applicable guidelines.

Both agenT-797 and Placebo

Intravenous infusion

Study details

Official title
Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
Sponsor
MiNK Therapeutics
Conditions
Pneumonia
Enrolling
90 people
Starts
2026-05-26
Est. completion
2027-08
Design
Quadruple-blind, randomized, sequential groups, Phase 2
Record
View on ClinicalTrials.gov ↗